Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10